- Home
- FATE vs ITIC Comparison
FATE vs ITIC Comparison
Compare FATE & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- ITIC
- Stock Information
- Founded
- FATE 2007
- ITIC 1972
- Country
- FATE United States
- ITIC United States
- Employees
- FATE N/A
- ITIC N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- ITIC Specialty Insurers
- Sector
- FATE Health Care
- ITIC Finance
- Exchange
- FATE Nasdaq
- ITIC Nasdaq
- Market Cap
- FATE 406.5M
- ITIC 404.7M
- IPO Year
- FATE 2013
- ITIC N/A
- Fundamental
- Price
- FATE $1.27
- ITIC $228.05
- Analyst Decision
- FATE Hold
- ITIC
- Analyst Count
- FATE 10
- ITIC 0
- Target Price
- FATE $6.75
- ITIC N/A
- AVG Volume (30 Days)
- FATE 3.2M
- ITIC 12.7K
- Earning Date
- FATE 02-24-2025
- ITIC 02-11-2025
- Dividend Yield
- FATE N/A
- ITIC 6.95%
- EPS Growth
- FATE N/A
- ITIC 22.45
- EPS
- FATE N/A
- ITIC 15.10
- Revenue
- FATE $13,447,000.00
- ITIC $241,018,000.00
- Revenue This Year
- FATE N/A
- ITIC N/A
- Revenue Next Year
- FATE N/A
- ITIC N/A
- P/E Ratio
- FATE N/A
- ITIC $15.10
- Revenue Growth
- FATE N/A
- ITIC 1.93
- 52 Week Low
- FATE $1.04
- ITIC $146.41
- 52 Week High
- FATE $8.83
- ITIC $290.40
- Technical
- Relative Strength Index (RSI)
- FATE 31.94
- ITIC 39.00
- Support Level
- FATE $1.22
- ITIC $225.24
- Resistance Level
- FATE $1.36
- ITIC $231.29
- Average True Range (ATR)
- FATE 0.15
- ITIC 6.06
- MACD
- FATE -0.02
- ITIC 0.26
- Stochastic Oscillator
- FATE 24.21
- ITIC 58.01
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About ITIC Investors Title Company
Investors Title Co operates primarily in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment primarily issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.